Travel-Associated Health Risks for Patients With Inflammatory Bowel Disease  Shomron Ben–Horin, Yoram Bujanover, Shulamit Goldstein, Moshe Nadler, Alon Lang, Uri Kopylov, Lior Katz, Adi Lahat, Eli Schwartz, Benjamin Avidan  Clinical Gastroenterology and Hepatology  Volume 10, Issue 2, Pages 160-165.e1 (February 2012) DOI: 10.1016/j.cgh.2011.10.025 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 The rate of illness during trips in the IBD and healthy control populations, stratified by countries of destinations. By definition, developing countries also include tropical countries, but the latter are also shown separately in the bars on the right for finer data presentation. Clinical Gastroenterology and Hepatology 2012 10, 160-165.e1DOI: (10.1016/j.cgh.2011.10.025) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 The distribution of the immunomodulating drugs used regularly during the trips by IBD patients. Clinical Gastroenterology and Hepatology 2012 10, 160-165.e1DOI: (10.1016/j.cgh.2011.10.025) Copyright © 2012 AGA Institute Terms and Conditions

Supplementary Figure 1 The rate of illness during travel in the immunosuppressed or immunocompetent IBD and healthy control populations. Clinical Gastroenterology and Hepatology 2012 10, 160-165.e1DOI: (10.1016/j.cgh.2011.10.025) Copyright © 2012 AGA Institute Terms and Conditions